NCT02048722View on ClinicalTrials.gov

Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 13, 2014

Primary Completion Date

October 14, 2019

Study Completion Date

October 12, 2021

Conditions
Adult AngiosarcomaRecurrent Adult Soft Tissue SarcomaStage III Adult Soft Tissue SarcomaStage IV Adult Soft Tissue Sarcoma
Interventions
DRUG

regorafenib

Given PO

Trial Locations (7)

52246

University of Iowa, Iowa City

55455

University of Minnesota Medical Center-Fairview, Minneapolis

55905

Mayo Clinic, Rochester

60611

Northwestern University, Chicago

63110

Washington University-St. Louis, St Louis

90403

Sarcoma Oncology Center, Santa Monica

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER